Everest MED (01952) Rises Over 3% as LERCHOL® Gains FDA Approval; BLA Submission Expected in Greater China in H1 2025

Stock News12-17

Everest MED (01952) surged more than 3%, reaching HK$48.44 by the time of writing, with a trading volume of HK$131 million. The company announced via its official WeChat account that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for LERCHOL® (lerodalcibep-liga) injection, a cardiovascular disease treatment developed by LIB Therapeutics. The drug is indicated to lower LDL-C levels in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), alongside diet and exercise.

In December 2025, Everest MED entered into a licensing agreement with Hisun Bio to secure exclusive rights for the clinical development, registration, and commercialization of LERCHOL® (lerodalcibep) in Greater China. LERCHOL® is a novel small-molecule protein-conjugated third-generation PCSK9 inhibitor designed to help patients achieve and maintain long-term LDL-C control.

As the first PCSK9 inhibitor fusion protein, LERCHOL® offers low immunogenicity and superior safety. Its patient-friendly features include once-monthly self-administration via a small-volume subcutaneous injection, extended room-temperature stability (up to three months), and portability for home or travel use. These advantages position LERCHOL® as a unique alternative to existing PCSK9 inhibitors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148000075?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148000075","market":"nz","top_or_hot":-1,"title":"Everest MED (01952) Rises Over 3% as LERCHOL® Gains FDA Approval; BLA Submission Expected in Greater China in H1 2025","media":"Stock News","content":"<p>Everest MED (01952) surged more than 3%, reaching HK$48.44 by the time of writing, with a trading volume of HK$131 million. The company announced via its official WeChat account that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for LERCHOL® (lerodalcibep-liga) injection, a cardiovascular disease treatment developed by LIB Therapeutics. The drug is indicated to lower LDL-C levels in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), alongside diet and exercise.</p>\n<p>In December 2025, Everest MED entered into a licensing agreement with Hisun Bio to secure exclusive rights for the clinical development, registration, and commercialization of LERCHOL® (lerodalcibep) in Greater China. LERCHOL® is a novel small-molecule protein-conjugated third-generation PCSK9 inhibitor designed to help patients achieve and maintain long-term LDL-C control.</p>\n<p>As the first PCSK9 inhibitor fusion protein, LERCHOL® offers low immunogenicity and superior safety. Its patient-friendly features include once-monthly self-administration via a small-volume subcutaneous injection, extended room-temperature stability (up to three months), and portability for home or travel use. These advantages position LERCHOL® as a unique alternative to existing PCSK9 inhibitors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Everest MED (01952) Rises Over 3% as LERCHOL® Gains FDA Approval; BLA Submission Expected in Greater China in H1 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEverest MED (01952) Rises Over 3% as LERCHOL® Gains FDA Approval; BLA Submission Expected in Greater China in H1 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-17 14:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Everest MED (01952) surged more than 3%, reaching HK$48.44 by the time of writing, with a trading volume of HK$131 million. The company announced via its official WeChat account that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for LERCHOL® (lerodalcibep-liga) injection, a cardiovascular disease treatment developed by LIB Therapeutics. The drug is indicated to lower LDL-C levels in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), alongside diet and exercise.</p>\n<p>In December 2025, Everest MED entered into a licensing agreement with Hisun Bio to secure exclusive rights for the clinical development, registration, and commercialization of LERCHOL® (lerodalcibep) in Greater China. LERCHOL® is a novel small-molecule protein-conjugated third-generation PCSK9 inhibitor designed to help patients achieve and maintain long-term LDL-C control.</p>\n<p>As the first PCSK9 inhibitor fusion protein, LERCHOL® offers low immunogenicity and superior safety. Its patient-friendly features include once-monthly self-administration via a small-volume subcutaneous injection, extended room-temperature stability (up to three months), and portability for home or travel use. These advantages position LERCHOL® as a unique alternative to existing PCSK9 inhibitors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"","article_id":"1148000075","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148000075","pubTimestamp":1765952882,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Everest MED (01952) surged more than 3%, reaching HK$48.44 by the time of writing, with a trading volume of HK$131 million. The company announced via its official WeChat account that the U.S. Food...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀","BK1574":"生物医药B类股","BK1161":"生物科技","BK1583":"高瓴概念"},"translate_title":"Everest MED(01952)涨超3%LERCHOL®获得FDA批准；预计2025年上半年在大中华区提交BLA","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"Everest MED (01952) surged more than 3%, reaching HK$48.44 by the time of writing, with a trading volume of HK$131 million. The company announced via its official WeChat account that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for LERCHOL® (lerodalcibep-liga) injection, a cardiovascular disease treatment developed by LIB Therapeutics. The drug is indicated to lower LDL-C levels in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), alongside diet and exercise.\nIn December 2025, Everest MED entered into a licensing agreement with Hisun Bio to secure exclusive rights for the clinical development, registration, and commercialization of LERCHOL® (lerodalcibep) in Greater China. LERCHOL® is a novel small-molecule protein-conjugated third-generation PCSK9 inhibitor designed to help patients achieve and maintain long-term LDL-C control.\nAs the first PCSK9 inhibitor fusion protein, LERCHOL® offers low immunogenicity and superior safety. Its patient-friendly features include once-monthly self-administration via a small-volume subcutaneous injection, extended room-temperature stability (up to three months), and portability for home or travel use. These advantages position LERCHOL® as a unique alternative to existing PCSK9 inhibitors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148000075","isCrawlerRequest":true}